Recent Developments in the Pharmaceutical Industry

NEW YORK, September 5, 2017 /PRNewswire/ --

According to a report by the Pharmaceutical Commerce (Market research firm Evaluate Pharma) in its annual World Preview report, projects a global growth rate for the pharma industry of 6.3% CAGR through 2022. By 2020, the pharma industry is estimated to be valued at about $1.12 trillion. The report indicates that according to Evaluate, the industry will rise at a faster rate during 2016-2020 period, then slow down because major patent expirations will come into effect. According to Evaluate, the prescription sales will reach $1.006 trillion in 2022, generics sales will increase from $73 billion in 2015 to $115 billion in 2022. There are some concerns regarding the growth potential of the industry, which is the result of political uncertainties in the developed world, including Brexit and rising skepticism in the U.S. over the worth of pharmaceuticals due to consistently increasing prices. Cosmos Holdings Inc. (OTC: COSM), CytRx Corporation  (NASDAQ: CYTR), Palatin Technologies, Inc. (NYSE: PTN), Aralez Pharmaceuticals Inc.  (NASDAQ: ARLZ), Immune Pharmaceuticals Inc. (NASDAQ: IMNP)

In the meantime, a report by Mordor Intelligence estimates that the global pharmaceutical contract manufacturing market will reach USD 94.38 billion by 2022, at a CAGR of 6.36% during the forecast period, from 2017 to 2022. Contract manufacturing refers to the outsourcing of certain production activities to third-party vendors. Pharmaceutical companies give the chemical formula of a drug to be manufactured to pharmaceutical contract manufacturers (CMO). "Major factors driving the growth of CMOs in the pharmaceutical industry are the growing need for state-of-the-art processes and production technologies, which have proven highly effective in meeting regulatory requirements," according to Mordor Intelligence.

Cosmos Holdings Inc. (OTCQB: COSM) is a fully reporting Pharmaceutical Holding Company that specializes, through its subsidiaries, in the wholesale of pharmaceutical products throughout Europe. Earlier today the company announced, "that it has engaged ROTH Capital Partners, LLC ("ROTH"), a leading investment banking and securities firm, to provide financial advisory services, in particular related to evaluating multiple financing options. ROTH will also focus on assisting the Company in creating and executing new strategies for maximizing shareholder value through its full scope of investment banking services. The Company does not have a defined timeline for a financing and cannot provide any assurance whether or when a financing will be announced or consummated."

About Cosmos Holdings Inc. - Cosmos Holdings Inc. is a pharmaceutical company focused on identifying, acquiring, developing, and commercializing medicines to improve patients' lives and outcomes. The Company has a trans-European network of more than 60 clients and vendors in Germany, the United Kingdom, Italy, France, Sweden, Ireland, Denmark, Poland, Netherlands, and Greece. Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece and In Harlow, UK. More information is available at

Palatin Technologies, Inc. (NYSE: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. On May 16, 2017, the company announced results for its third quarter ended March 31, 2017. Palatin reported a net loss of $(3.6) million, or $(0.02) per basic and diluted share, for the quarter ended March 31, 2017, compared to a net loss of $(12.7) million, or $(0.08) per basic and diluted share, for the same period in 2016. Total operating expenses for the quarter ended March 31, 2017 were $13.8 million compared to $12.1 million for the comparable quarter of 2016. The increase in operating expenses was predominately attributable to professional services incurred related to closing our license agreement with AMAG.    

CytRx Corporation (NASDAQ: CYTR) is a biopharmaceutical company specializing in research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. On July 28, 2017, the company announced that it has entered into a global strategic license with NantCell, Inc., for the exclusive rights to develop and commercialize aldoxorubicin for all indications. NantCell, a private subsidiary of NantWorks, LLC, is a clinical stage immuno-oncology company focused on developing novel molecularly targeted therapeutics including antibody, T-cell and NK cell based treatments for patients with cancer. 

Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Recently, the company announced financial results for the second quarter and first half of 2017. The Company also highlighted certain corporate and commercial updates. On June 27, 2017, the Company announced that the United States District Court for the District of New Jersey upheld the validity of two patents covering Vimovo(R) owned by a subsidiary of Aralez and licensed to Horizon Pharma, and further held that each defendant would infringe at least one of the two Aralez subsidiary's patents with their proposed generic naproxen/esomeprazole magnesium products. 

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) is dedicated to alleviating the burden of patients suffering from autoimmune diseases by developing novel immunotherapeutic agents. Immune's lead product candidate, bertilimumab, is in Phase 2 clinical development for bullous pemphigoid, an orphan autoimmune dermatological condition, and for ulcerative colitis. The company recently announced the publication of clinical trial results on the use of Ceplene for relapse prevention in patients with acute myeloid leukemia. The results were published in the leading hematology journal, Leukemia, published by Springer Nature. Investigators from the Universities of Gothenburg, Sweden and Rome, Italy reported that functional NK cells are clinically relevant anti-leukemic effector cells in AML patients who received treatment with Ceplene/IL-2.

Please Sign Up Now at to Receive Alerts on Trending Financial News from all these companies. 'The Latest Buzz in Financial News'

Subscribe Now! Watch us report from NYSE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, has been compensated three thousand dollars for financial news dissemination and PR services by a non-affiliate third party for Cosmos Holdings Inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit:


        For further information: